Published in AIDS Weekly, August 16th, 2004
"HIV-1 integrase is a critical enzyme for replication of HIV, and its inhibition is one of the most promising new drug targets for anti-retroviral therapy with potentially significant advantages over existing therapies," investigators in the United States wrote."
The "isolation, structure elucidation, and absolute stereochemistry of integrasone, a novel polyketide, derived from an unidentified sterile mycelium" is described," said K.B. Herath and colleagues.
The authors reported, "This bicyclic dihydroxy epoxide lactone inhibited the strand transfer reaction of HIV-1...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.